What is Terlipressin?
Terlipressin is used as a vasoactive drug in the management of hypotension, hepatorenal syndrome and for the treatment of bleeding oesophageal varices. It is similar to vasopressin, is a prohormone of lysine‐vasopressin. It is the drug of choice for the treatment of hepatorenal syndrome and mostly used for the same.
Global Terlipressin Market Outlook
The increasing occurrence of liver and kidney deceases with impaired kidney function that is hepatorenal syndrome is stimulating the growth of the terlipressin market. The prevalence of the hepatorenal syndrome is unidentified but is predicted to occur in approximately 8-10 percent of individuals. Terlipressin delivers longer biological activity and comparatively lesser side effects than vasopressin and is effective in controlling AVB. It reduces failure to control bleeding and mortality, is the first choice for pharmacological therapy when available.
The use of terlipressin as a drug has been proved to be safe, with minimal side effects that usually disappear after dose reduction, and results in an improved outcome in patients with hepatorenal syndrome. It is approved for use in Europe for patients with hepatorenal syndrome and trials to get it approved in the US are in progress. During findings, it has been found that terlipressin is studied the most for individuals with the hepatorenal syndrome and results have shown improved renal function in affected individuals than alternatives. Availability issues are restraining the growth of the terlipressin market. At present, terlipressin is not available in the United States and Canada. But is available in New Zealand, Australia, much of Europe, India & UAE and Pakistan. Easy availability of alternatives such as somatostatin, octreotide, and vapreotide restrains the growth of the market.
Global Terlipressin Market Competitive Landscape
The "Global Terlipressin Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such EVER Pharma, Hybio Pharmaceutical, Sun Pharmaceutical Industries Ltd., Shanghai Soho-Yiming Pharmaceuticals, Xi ‘an langene biological technology, SGPharma, Maya Biotech and Hangzhou Huadi Group. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis.
Customization of the Report
• In case of any queries or customization requirements please connect with our sales team, who will ensure that your requirements are met.
1. INTRODUCTION OF GLOBAL TERLIPRESSIN MARKET
1.1. Overview of the Market
1.2. Scope of Report
1.3. Assumptions
2. EXECUTIVE SUMMARY
3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1. Data Mining
3.2. Validation
3.3. Primary Interviews
3.4. List of Data Sources
4. GLOBAL TERLIPRESSIN MARKET OUTLOOK
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Porters Five Force Model
4.4. Value Chain Analysis
5. GLOBAL TERLIPRESSIN MARKET, BY TYPE
5.1. Overview
5.2. Injection
5.3. Other
6. GLOBAL TERLIPRESSIN MARKET, BY TYPE
6.1. Overview
6.2. ≥98%
6.3. <98%
7. GLOBAL TERLIPRESSIN MARKET, BY GEOGRAPHY
7.1. Overview
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.3. Europe
7.3.1. Germany
7.3.2. U.K.
7.3.3. France
7.3.4. Rest of Europe
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. Rest of Asia Pacific
7.5. Rest of the World
7.5.1. Latin America
7.5.2. Middle East & Africa
8. GLOBAL TERLIPRESSIN MARKET COMPETITIVE LANDSCAPE
8.1. Overview
8.2. Company Market Ranking
8.3. Key Development Strategies
9. COMPANY PROFILES
9.1. EVER Pharma
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
9.2. Hybio Pharmaceutical
9.2.1. Overview
9.2.2. Financial Performance
9.2.3. Product Outlook
9.2.4. Key Developments
9.3. Sun Pharmaceutical Industries Ltd.
9.3.1. Overview
9.3.2. Financial Performance
9.3.3. Product Outlook
9.3.4. Key Developments
9.4. Shanghai Soho-Yiming Pharmaceuticals
9.4.1. Overview
9.4.2. Financial Performance
9.4.3. Product Outlook
9.4.4. Key Developments
9.5. Xi ‘an langene biological technology
9.5.1. Overview
9.5.2. Financial Performance
9.5.3. Product Outlook
9.5.4. Key Developments
9.6. SGPharma
9.6.1. Overview
9.6.2. Financial Performance
9.6.3. Product Outlook
9.6.4. Key Developments
9.7. Maya Biotech
9.7.1. Overview
9.7.2. Financial Performance
9.7.3. Product Outlook
9.7.4. Key Developments
9.8. Hangzhou Huadi Group
9.8.1. Overview
9.8.2. Financial Performance
9.8.3. Product Outlook
9.8.4. Key Developments
10. Appendix
10.1. Related Reports
| Price : US$ 3500 | Date : Aug 2023 |
| Category : Healthcare and Pharmaceuticals | Pages : 148 |
| Price : US$ 3500 | Date : Oct 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 160 |
| Price : US$ 3500 | Date : May 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 95 |
| Price : US$ 3500 | Date : Jun 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 95 |
| Price : US$ 3500 | Date : Jun 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 95 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
